id: 28935719 Error occurred: The following PMID is not available: 28935719

PMID- 28945942
OWN - NLM
STAT- MEDLINE
DCOM- 20180731
LR  - 20180815
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 35
IP  - 1
DP  - 2018 Jan
TI  - Inequalities in glycaemic control, hypoglycaemia and diabetic ketoacidosis
      according to socio-economic status and area-level deprivation in Type 1 diabetes 
      mellitus: a systematic review.
PG  - 12-32
LID - 10.1111/dme.13519 [doi]
AB  - AIM: The aim of this systematic review was to examine the associations of
      individual-level as well as area-level socio-economic status and area-level
      deprivation with glycaemic control, hypoglycaemia and diabetic ketoacidosis in
      people with Type 1 diabetes mellitus. METHODS: Ovid MEDLINE was searched to
      identify relevant cohort, case-control or cross-sectional studies published
      between January 2000 and June 2015. Search results were screened by title,
      abstract and keywords to identify eligible publications. Decisions on inclusion
      or exclusion of full texts were made independently by two reviewers. The
      Newcastle-Ottawa Scale was used to estimate the methodological quality of
      included studies. Quality assessment and extracted data of included studies were 
      synthesized narratively and reported according to the PRISMA statement. RESULTS: 
      Literature search in Ovid MEDLINE identified 1345 eligible studies. Twenty
      studies matched our inclusion and exclusion criteria. Two articles were
      additionally identified through hand search. According to the Newcastle-Ottawa
      Scale, most of the studies were of average quality. Results on associations of
      socio-economic status and area-level deprivation with glycaemic control and
      hypoglycaemia were contradictory between studies. By contrast, lower
      socio-economic status and higher area-level deprivation were associated with a
      higher risk for diabetic ketoacidosis in all except one study. CONCLUSIONS: Lower
      socio-economic status and higher area-level deprivation are associated with a
      higher risk of experiencing diabetic ketoacidosis in people with Type 1 diabetes 
      mellitus. Access to care for socially deprived people needs to be expanded to
      overcome impairing effects on the course of the condition and to reduce
      healthcare disparities.
CI  - (c) 2017 Diabetes UK.
FAU - Lindner, L M E
AU  - Lindner LME
AUID- ORCID: 0000-0003-2068-7420
AD  - Institute for Biometrics and Epidemiology, German Diabetes Centre, Leibniz Centre
      for Diabetes Research at Heinrich-Heine-University Dusseldorf, Dusseldorf,
      Germany.
AD  - German Centre for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
FAU - Rathmann, W
AU  - Rathmann W
AD  - Institute for Biometrics and Epidemiology, German Diabetes Centre, Leibniz Centre
      for Diabetes Research at Heinrich-Heine-University Dusseldorf, Dusseldorf,
      Germany.
AD  - German Centre for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
FAU - Rosenbauer, J
AU  - Rosenbauer J
AD  - Institute for Biometrics and Epidemiology, German Diabetes Centre, Leibniz Centre
      for Diabetes Research at Heinrich-Heine-University Dusseldorf, Dusseldorf,
      Germany.
AD  - German Centre for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
DEP - 20171103
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 1/*drug therapy/metabolism
MH  - Diabetic Ketoacidosis/*epidemiology
MH  - Glycated Hemoglobin A/metabolism
MH  - *Health Status Disparities
MH  - *Healthcare Disparities
MH  - Humans
MH  - Hypoglycemia/chemically induced/*epidemiology
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - *Social Class
EDAT- 2017/09/26 06:00
MHDA- 2018/08/01 06:00
CRDT- 2017/09/26 06:00
PHST- 2017/09/19 00:00 [accepted]
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2018/08/01 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
AID - 10.1111/dme.13519 [doi]
PST - ppublish
SO  - Diabet Med. 2018 Jan;35(1):12-32. doi: 10.1111/dme.13519. Epub 2017 Nov 3.

PMID- 28945928
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20180802
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 34
IP  - 12
DP  - 2017 Dec
TI  - Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of
      clinical outcomes from randomized controlled trials and real-world data.
PG  - 1728-1736
LID - 10.1111/dme.13518 [doi]
AB  - AIM: To evaluate the concordance between data derived from randomized controlled 
      trial (RCT) and real-world estimates of HbA1c and weight change after 24 weeks of
      initiation of a basal-bolus compared with a premixed insulin regimen in people
      with Type 2 diabetes. METHODS: Data eight RCTs were pooled after a systematic
      review of studies examining basal-bolus (n = 1893) or premixed (n = 1517)
      regimens. Real-world data were extracted from the UK primary care dataset for
      people on basal-bolus (n = 7483) or premixed insulin regimens (n=10 744). The
      mean differences between HbA1c and weight from baseline were calculated using
      t-tests, while analysis of variance was used to compare the two treatment
      regimens. Linear regression analyses were used to determine the predictors of
      this change. RESULTS: Both insulin regimens were associated with HbA1c reductions
      (real-world data -0.28%; RCT data, -1.4%) and weight gain (real-world data, +0.27
      kg; RCT data, +2.96 kg) but there were no significant differences between
      basal-bolus and premixed insulin. Discordances in the pattern of treatment
      response were observed, however, between real-world and RCT data for both insulin
      regimens. For any given baseline HbA1c concentration, the change in HbA1c in the 
      RCTs was greater than in real-world conditions and for those with baseline weight
      above ~60 kg, RCT data showed overall weight gain in contrast to slight weight
      loss in the real-world population. Lastly, for both randomized controlled trial
      and real-world populations, while greater baseline weight was associated with
      reduced response to treatment, the association was much steeper in the RCT than
      in the real-world population. In addition, greater baseline weight was associated
      with greater weight reductions in both premixed insulin and basal-bolus insulin
      regimens, although to a lesser extent with the latter. CONCLUSION: These results 
      highlight specific discrepancies in the HbA1c reduction and weight change in
      insulin regimen between real world versus RCT populations; with greater reduction
      in HbA1c and greater increase in weight observed in the RCT population than in
      the real-world population. Also, the basal-bolus regimens in both real-world and 
      RCT populations showed greater reduction in HbA1c compared to the premix regimen 
      (though more marked in RCTs), while the premix regimen showed greater increase in
      weight in real-world, as against basal-bolus in the RCT population.
CI  - (c) 2017 Diabetes UK.
FAU - Anyanwagu, U
AU  - Anyanwagu U
AUID- ORCID: 0000-0003-0530-3564
AD  - Division of Medical Sciences and Graduate Entry Medicine, School of Medicine,
      University of Nottingham, Nottingham, UK.
FAU - Mamza, J
AU  - Mamza J
AD  - Division of Medical Sciences and Graduate Entry Medicine, School of Medicine,
      University of Nottingham, Nottingham, UK.
FAU - Gordon, J
AU  - Gordon J
AD  - Division of Medical Sciences and Graduate Entry Medicine, School of Medicine,
      University of Nottingham, Nottingham, UK.
FAU - Donnelly, R
AU  - Donnelly R
AD  - Division of Medical Sciences and Graduate Entry Medicine, School of Medicine,
      University of Nottingham, Nottingham, UK.
FAU - Idris, I
AU  - Idris I
AUID- ORCID: 0000-0002-7548-8288
AD  - Division of Medical Sciences and Graduate Entry Medicine, School of Medicine,
      University of Nottingham, Nottingham, UK.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20171014
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Drug Compounding
MH  - Drug Dosage Calculations
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Observational Studies as Topic/statistics & numerical data
MH  - Primary Health Care/statistics & numerical data
MH  - Randomized Controlled Trials as Topic/statistics & numerical data
MH  - Treatment Outcome
MH  - United Kingdom/epidemiology
EDAT- 2017/09/26 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/09/26 06:00
PHST- 2017/09/19 00:00 [accepted]
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
AID - 10.1111/dme.13518 [doi]
PST - ppublish
SO  - Diabet Med. 2017 Dec;34(12):1728-1736. doi: 10.1111/dme.13518. Epub 2017 Oct 14.

PMID- 28945922
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20180802
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 34
IP  - 12
DP  - 2017 Dec
TI  - Attenuated heart rate recovery predicts risk of incident diabetes: insights from 
      a meta-analysis.
PG  - 1676-1683
LID - 10.1111/dme.13517 [doi]
AB  - AIMS: To assess the association between attenuated heart rate recovery, a
      non-invasive measure of autonomic dysfunction, and risk of diabetes in the
      general population. METHODS: Databases were searched for cohort studies up to May
      2017 that reported the association of heart rate recovery with the risk of
      diabetes. The overall hazard ratios for slowest vs fastest heart rate recovery
      (the referent) and for every 10-beats-per-min decrement in heart rate recovery
      were calculated using a random effects meta-analysis model. RESULTS: Four cohort 
      studies with 430 incident cases of diabetes among a total of 9113 participants
      during a mean follow-up period of 8.1 years were included. Results showed that
      the slowest heart rate recovery was associated with a higher risk of diabetes
      (hazard ratio 1.66, 95% CI 1.16 to 2.38) vs the fastest heart rate recovery, and 
      the hazard ratio of risk of diabetes for every 10-beats-per-min decrement in
      heart rate recovery was 1.29 (95% CI 1.13 to 1.48). No significant interaction
      effect was observed regarding the efficacy of 1-min and 2-min heart rate recovery
      in predicting risk of diabetes (both Pfor interaction >0.60); however, a linear
      dose-response relationship existed for overall studies and for studies using
      1-min heart rate recovery as the exposure (both P >0.60 for non-linearity).
      CONCLUSIONS: Attenuated heart rate recovery is associated with an increased risk 
      of diabetes in a dose-dependent manner, and measurement of heart rate recovery is
      worth recommending as part of diabetes risk assessment in clinical routines.
CI  - (c) 2017 Diabetes UK.
FAU - Qiu, S H
AU  - Qiu SH
AD  - Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of
      Medicine, Southeast University, Nanjing, P. R. China.
FAU - Xue, C
AU  - Xue C
AD  - Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of
      Medicine, Southeast University, Nanjing, P. R. China.
FAU - Sun, Z L
AU  - Sun ZL
AUID- ORCID: 0000-0003-1865-1429
AD  - Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of
      Medicine, Southeast University, Nanjing, P. R. China.
FAU - Steinacker, J M
AU  - Steinacker JM
AD  - Division of Sports and Rehabilitation Medicine, Ulm University Medical Centre,
      Ulm, Germany.
FAU - Zugel, M
AU  - Zugel M
AD  - Division of Sports and Rehabilitation Medicine, Ulm University Medical Centre,
      Ulm, Germany.
FAU - Schumann, U
AU  - Schumann U
AD  - Division of Sports and Rehabilitation Medicine, Ulm University Medical Centre,
      Ulm, Germany.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Research Support, Non-U.S. Gov't
DEP - 20171017
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
SB  - IM
MH  - Cardiovascular Diseases/complications/diagnosis/epidemiology/*physiopathology
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*diagnosis/epidemiology/*physiopathology
MH  - Heart Rate/*physiology
MH  - Humans
MH  - Incidence
MH  - Prognosis
MH  - Recovery of Function/physiology
MH  - Risk Factors
EDAT- 2017/09/26 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/09/26 06:00
PHST- 2017/09/19 00:00 [accepted]
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
AID - 10.1111/dme.13517 [doi]
PST - ppublish
SO  - Diabet Med. 2017 Dec;34(12):1676-1683. doi: 10.1111/dme.13517. Epub 2017 Oct 17.

PMID- 28945282
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20180802
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 34
IP  - 12
DP  - 2017 Dec
TI  - High risk of conversion to diabetes in first-degree relatives of individuals with
      young-onset type 2 diabetes: a 12-year follow-up analysis.
PG  - 1701-1709
LID - 10.1111/dme.13516 [doi]
AB  - AIM: Family history of diabetes is an established risk factor for Type 2
      diabetes, but the impact of a family history of young-onset diabetes (onset < 40 
      years) on future risk of diabetes among first-degree relatives is unclear. In
      this prospective study, we examined the influence of family history of late-
      versus young-onset diabetes on the development of diabetes in a young to
      middle-aged Chinese population. METHODS: Some 365 siblings identified through
      probands with Type 2 diabetes and 452 participants from a community-based health 
      awareness project (aged 18-55 years) who underwent metabolic assessment during
      the period 1998-2002 were followed to 2012-2013 to determine their glycaemic
      status. Multivariate logistic regression was performed to investigate the
      association of family history of diabetes presented at different age categories
      with development of diabetes. RESULTS: In this cohort, 53.4% (n = 167) of
      participants with a family history of young-onset diabetes, 30.1% (n = 68) of
      those with a family history of late-onset diabetes and 14.4% (n = 40) of those
      without a family history developed diabetes. Using logistic regression, family
      history of diabetes presented at ages >/= 50, 40-49, 30-39 and < 30 years,
      increased conversion to diabetes with respective odds ratios of 2.4, 5.8, 9.4 and
      7.0 (P < 0.001 for all), after adjustment for socio-economic status, smoking,
      obesity, hypertension and dyslipidaemia. Among participants without diabetes at
      baseline, risk association of family history of late-onset diabetes with incident
      diabetes was not sustained, whereas that of family history of young-onset
      diabetes remained robust on further adjustment for baseline glycaemic
      measurements. CONCLUSIONS: First-degree relatives of people with Type 2 diabetes,
      especially relatives of those with young-onset diabetes, are at high risk for
      diabetes.
CI  - (c) 2017 Diabetes UK.
FAU - Zhang, Y
AU  - Zhang Y
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
FAU - Luk, A O Y
AU  - Luk AOY
AUID- ORCID: 0000-0002-5244-6069
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
AD  - Hong Kong Institute of Diabetes and Obesity, Chinese University of Hong Kong,
      Prince of Wales Hospital, Hong Kong.
AD  - Li Ka Shing Institute of Health and Sciences, Chinese University of Hong Kong,
      Prince of Wales Hospital, Hong Kong.
FAU - Chow, E
AU  - Chow E
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
FAU - Ko, G T C
AU  - Ko GTC
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
FAU - Chan, M H M
AU  - Chan MHM
AD  - Department of Chemical Pathology, Chinese University of Hong Kong, Prince of
      Wales Hospital, Hong Kong.
FAU - Ng, M
AU  - Ng M
AD  - Department of Haematology, Chinese University of Hong Kong, Prince of Wales
      Hospital, Hong Kong.
FAU - Kong, A P S
AU  - Kong APS
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
AD  - Hong Kong Institute of Diabetes and Obesity, Chinese University of Hong Kong,
      Prince of Wales Hospital, Hong Kong.
AD  - Li Ka Shing Institute of Health and Sciences, Chinese University of Hong Kong,
      Prince of Wales Hospital, Hong Kong.
FAU - Ma, R C W
AU  - Ma RCW
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
AD  - Hong Kong Institute of Diabetes and Obesity, Chinese University of Hong Kong,
      Prince of Wales Hospital, Hong Kong.
AD  - Li Ka Shing Institute of Health and Sciences, Chinese University of Hong Kong,
      Prince of Wales Hospital, Hong Kong.
FAU - Ozaki, R
AU  - Ozaki R
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
FAU - So, W Y
AU  - So WY
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
FAU - Chow, C C
AU  - Chow CC
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
FAU - Chan, J C N
AU  - Chan JCN
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong.
AD  - Hong Kong Institute of Diabetes and Obesity, Chinese University of Hong Kong,
      Prince of Wales Hospital, Hong Kong.
AD  - Li Ka Shing Institute of Health and Sciences, Chinese University of Hong Kong,
      Prince of Wales Hospital, Hong Kong.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171014
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Diabetes Mellitus, Type 2/*epidemiology
MH  - Disease Progression
MH  - *Family
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prediabetic State/*epidemiology/pathology
MH  - Risk Factors
MH  - Young Adult
EDAT- 2017/09/26 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/09/26 06:00
PHST- 2017/09/19 00:00 [accepted]
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
AID - 10.1111/dme.13516 [doi]
PST - ppublish
SO  - Diabet Med. 2017 Dec;34(12):1701-1709. doi: 10.1111/dme.13516. Epub 2017 Oct 14.

PMID- 28951389
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20180316
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 66
IP  - 12
DP  - 2017 Dec
TI  - Genetically Determined Plasma Lipid Levels and Risk of Diabetic Retinopathy: A
      Mendelian Randomization Study.
PG  - 3130-3141
LID - 10.2337/db17-0398 [doi]
AB  - Results from observational studies examining dyslipidemia as a risk factor for
      diabetic retinopathy (DR) have been inconsistent. We evaluated the causal
      relationship between plasma lipids and DR using a Mendelian randomization
      approach. We pooled genome-wide association studies summary statistics from 18
      studies for two DR phenotypes: any DR (N = 2,969 case and 4,096 control subjects)
      and severe DR (N = 1,277 case and 3,980 control subjects). Previously identified 
      lipid-associated single nucleotide polymorphisms served as instrumental
      variables. Meta-analysis to combine the Mendelian randomization estimates from
      different cohorts was conducted. There was no statistically significant change in
      odds ratios of having any DR or severe DR for any of the lipid fractions in the
      primary analysis that used single nucleotide polymorphisms that did not have a
      pleiotropic effect on another lipid fraction. Similarly, there was no significant
      association in the Caucasian and Chinese subgroup analyses. This study did not
      show evidence of a causal role of the four lipid fractions on DR. However, the
      study had limited power to detect odds ratios less than 1.23 per SD in
      genetically induced increase in plasma lipid levels, thus we cannot exclude that 
      causal relationships with more modest effect sizes exist.
CI  - (c) 2017 by the American Diabetes Association.
FAU - Sobrin, Lucia
AU  - Sobrin L
AD  - Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear,
      Boston, MA.
FAU - Chong, Yong He
AU  - Chong YH
AD  - Duke-NUS Medical School, National University of Singapore, Singapore.
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
FAU - Fan, Qiao
AU  - Fan Q
AD  - Duke-NUS Medical School, National University of Singapore, Singapore.
FAU - Gan, Alfred
AU  - Gan A
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
FAU - Stanwyck, Lynn K
AU  - Stanwyck LK
AD  - Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear,
      Boston, MA.
FAU - Kaidonis, Georgia
AU  - Kaidonis G
AD  - Department of Ophthalmology, Flinders University, Adelaide, South Australia,
      Australia.
FAU - Craig, Jamie E
AU  - Craig JE
AD  - Department of Ophthalmology, Flinders University, Adelaide, South Australia,
      Australia.
FAU - Kim, Jihye
AU  - Kim J
AD  - Human Genetics Center, The University of Texas Health Science Center at Houston, 
      Houston, TX.
FAU - Liao, Wen-Ling
AU  - Liao WL
AD  - Graduate Institute of Integrated Medicine, China Medical University, Taichung,
      Taiwan.
AD  - Center for Personalized Medicine, China Medical University Hospital, Taichung,
      Taiwan.
FAU - Huang, Yu-Chuen
AU  - Huang YC
AD  - School of Chinese Medicine, China Medical University, Taichung, Taiwan.
AD  - Genetic Center, Department of Medical Research, China Medical University
      Hospital, Taichung, Taiwan.
FAU - Lee, Wen-Jane
AU  - Lee WJ
AD  - Department of Medical Research, Taichung Veterans General Hospital, Taichung,
      Taiwan.
FAU - Hung, Yi-Jen
AU  - Hung YJ
AD  - Department of Internal Medicine, Tri-Service General Hospital, Taipei City,
      Taiwan.
FAU - Guo, Xiuqing
AU  - Guo X
AD  - Institute for Translational Genomics and Population Sciences, LA BioMed, and
      Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA.
FAU - Hai, Yang
AU  - Hai Y
AD  - Institute for Translational Genomics and Population Sciences, LA BioMed, and
      Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA.
FAU - Ipp, Eli
AU  - Ipp E
AD  - Department of Medicine, LA BioMed, Harbor-UCLA Medical Center, Torrance, CA.
FAU - Pollack, Samuela
AU  - Pollack S
AD  - Department of Statistical Genetics, Harvard T.H. Chan School of Public Health,
      Boston, MA.
FAU - Hancock, Heather
AU  - Hancock H
AD  - Department of Ophthalmology, The University of Mississippi Medical Center,
      Jackson, MS.
FAU - Price, Alkes
AU  - Price A
AD  - Department of Statistical Genetics, Harvard T.H. Chan School of Public Health,
      Boston, MA.
FAU - Penman, Alan
AU  - Penman A
AD  - Department of Medicine, The University of Mississippi Medical Center, Jackson,
      MS.
FAU - Mitchell, Paul
AU  - Mitchell P
AD  - Centre for Vision Research, The Westmead Institute for Medical Research,
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Liew, Gerald
AU  - Liew G
AD  - Centre for Vision Research, The Westmead Institute for Medical Research,
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Smith, Albert V
AU  - Smith AV
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
AD  - Icelandic Heart Association, Kopavogur, Iceland.
FAU - Gudnason, Vilmundur
AU  - Gudnason V
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
AD  - Icelandic Heart Association, Kopavogur, Iceland.
FAU - Tan, Gavin
AU  - Tan G
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
FAU - Klein, Barbara E K
AU  - Klein BEK
AD  - Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison,
      Madison, WI.
FAU - Kuo, Jane
AU  - Kuo J
AD  - Institute for Translational Genomics and Population Sciences, LA BioMed, and
      Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA.
AD  - Clinical and Medical Affairs, CardioDx, Inc., Redwood City, CA.
FAU - Li, Xiaohui
AU  - Li X
AD  - Institute for Translational Genomics and Population Sciences, LA BioMed, and
      Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA.
FAU - Christiansen, Mark W
AU  - Christiansen MW
AD  - Cardiovascular Health Research Unit, Division of General Internal Medicine,
      University of Washington, Seattle, WA.
FAU - Psaty, Bruce M
AU  - Psaty BM
AD  - Cardiovascular Health Research Unit, Division of General Internal Medicine,
      University of Washington, Seattle, WA.
AD  - Kaiser Permanente Washington Health Research Institute, Seattle, WA.
FAU - Sandow, Kevin
AU  - Sandow K
AD  - Institute for Translational Genomics and Population Sciences, LA BioMed, and
      Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA.
CN  - Asian Genetic Epidemiology Network Consortium
FAU - Jensen, Richard A
AU  - Jensen RA
AD  - Cardiovascular Health Research Unit, Division of General Internal Medicine,
      University of Washington, Seattle, WA.
FAU - Klein, Ronald
AU  - Klein R
AD  - Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison,
      Madison, WI.
FAU - Cotch, Mary Frances
AU  - Cotch MF
AD  - Division of Epidemiology and Clinical Applications, National Eye Institute,
      National Institutes of Health, Bethesda, MD.
FAU - Wang, Jie Jin
AU  - Wang JJ
AD  - Duke-NUS Medical School, National University of Singapore, Singapore.
AD  - Centre for Vision Research, The Westmead Institute for Medical Research,
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Jia, Yucheng
AU  - Jia Y
AD  - Institute for Translational Genomics and Population Sciences, LA BioMed, and
      Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA.
FAU - Chen, Ching J
AU  - Chen CJ
AD  - Department of Ophthalmology, The University of Mississippi Medical Center,
      Jackson, MS.
FAU - Chen, Yii-Der Ida
AU  - Chen YI
AD  - Institute for Translational Genomics and Population Sciences, LA BioMed, and
      Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA.
FAU - Rotter, Jerome I
AU  - Rotter JI
AD  - Institute for Translational Genomics and Population Sciences, LA BioMed, and
      Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA.
FAU - Tsai, Fuu-Jen
AU  - Tsai FJ
AD  - School of Chinese Medicine, China Medical University, Taichung, Taiwan.
AD  - Departments of Medical Genetics, Pediatrics, and Medical Research, China Medical 
      University Hospital, Tiachung, Tiawan.
FAU - Hanis, Craig L
AU  - Hanis CL
AD  - Human Genetics Center, The University of Texas Health Science Center at Houston, 
      Houston, TX.
FAU - Burdon, Kathryn P
AU  - Burdon KP
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania,
      Australia.
FAU - Wong, Tien Yin
AU  - Wong TY
AD  - Duke-NUS Medical School, National University of Singapore, Singapore.
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University
      of Singapore, Singapore.
FAU - Cheng, Ching-Yu
AU  - Cheng CY
AUID- ORCID: 0000-0003-0655-885X
AD  - Duke-NUS Medical School, National University of Singapore, Singapore
      chingyu.cheng@duke-nus.edu.sg.
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University
      of Singapore, Singapore.
LA  - eng
GR  - HHSN268201500003C/HL/NHLBI NIH HHS/United States
GR  - N01HC95160/HL/NHLBI NIH HHS/United States
GR  - N01HC95163/HL/NHLBI NIH HHS/United States
GR  - U01 HL080295/HL/NHLBI NIH HHS/United States
GR  - UL1 TR001079/TR/NCATS NIH HHS/United States
GR  - U01 HL130114/HL/NHLBI NIH HHS/United States
GR  - HHSN268200800007C/HL/NHLBI NIH HHS/United States
GR  - N01HC95169/HL/NHLBI NIH HHS/United States
GR  - K12 EY016335/EY/NEI NIH HHS/United States
GR  - HHSN268201300048C/HL/NHLBI NIH HHS/United States
GR  - N01HC95164/HL/NHLBI NIH HHS/United States
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
GR  - N01HC55222/HL/NHLBI NIH HHS/United States
GR  - N02HL64278/HL/NHLBI NIH HHS/United States
GR  - N01HC95162/HL/NHLBI NIH HHS/United States
GR  - N01HC85086/HL/NHLBI NIH HHS/United States
GR  - R01 HL105756/HL/NHLBI NIH HHS/United States
GR  - N01HC95168/HL/NHLBI NIH HHS/United States
GR  - P30 DK063491/DK/NIDDK NIH HHS/United States
GR  - HHSN268201300049C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201200036C/HL/NHLBI NIH HHS/United States
GR  - N01HC95165/HL/NHLBI NIH HHS/United States
GR  - N01HC95159/HL/NHLBI NIH HHS/United States
GR  - N01HC95161/HL/NHLBI NIH HHS/United States
GR  - HHSN268201300047C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201300050C/HL/NHLBI NIH HHS/United States
GR  - ZIA AG007380/AG/NIA NIH HHS/United States
GR  - N01HC85082/HL/NHLBI NIH HHS/United States
GR  - N01HC75150/HL/NHLBI NIH HHS/United States
GR  - N01HC95167/HL/NHLBI NIH HHS/United States
GR  - N01HC85083/HL/NHLBI NIH HHS/United States
GR  - UL1 TR000040/TR/NCATS NIH HHS/United States
GR  - Wellcome Trust/United Kingdom
GR  - HHSN268201300046C/HL/NHLBI NIH HHS/United States
GR  - N01HC85079/HL/NHLBI NIH HHS/United States
GR  - N01HC95166/HL/NHLBI NIH HHS/United States
GR  - R01 EY022302/EY/NEI NIH HHS/United States
GR  - R01 AG023629/AG/NIA NIH HHS/United States
GR  - UL1 TR001881/TR/NCATS NIH HHS/United States
GR  - N01HC85080/HL/NHLBI NIH HHS/United States
GR  - ZIA EY000401/EY/NEI NIH HHS/United States
GR  - N01HC85081/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170926
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Lipids)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Diabetic Retinopathy/blood/*etiology
MH  - Female
MH  - Genome-Wide Association Study
MH  - Humans
MH  - Lipids/*blood
MH  - Male
MH  - *Mendelian Randomization Analysis
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Risk
PMC - PMC5697951
IR  - Spracklen CN
FIR - Spracklen, Cassandra N
IR  - Chen P
FIR - Chen, Peng
IR  - Kim YJ
FIR - Kim, Young Jin
IR  - Wang X
FIR - Wang, Xu
IR  - Cai H
FIR - Cai, Hui
IR  - Li S
FIR - Li, Shengxu
IR  - Long J
FIR - Long, Jirong
IR  - Wu Y
FIR - Wu, Ying
IR  - Wang YX
FIR - Wang, Ya-Xing
IR  - Takeuchi F
FIR - Takeuchi, Fumihiko
IR  - Wu JY
FIR - Wu, Jer-Yuarn
IR  - Jung KJ
FIR - Jung, Keum-Ji
IR  - Hu C
FIR - Hu, Cheng
IR  - Akiyama K
FIR - Akiyama, Koichi
IR  - Zhang Y
FIR - Zhang, Yonghong
IR  - Moon S
FIR - Moon, Sanghoon
IR  - Johnson TA
FIR - Johnson, Todd A
IR  - Li H
FIR - Li, Huaixing
IR  - Dorajoo R
FIR - Dorajoo, Rajkumar
IR  - He M
FIR - He, Meian
IR  - Cannon ME
FIR - Cannon, Maren E
IR  - Roman TS
FIR - Roman, Tamara S
IR  - Salfati E
FIR - Salfati, Elias
IR  - Lin KH
FIR - Lin, Keng-Hung
IR  - Sheu WHH
FIR - Sheu, Wayne H H
IR  - Absher D
FIR - Absher, Devin
IR  - Adair LS
FIR - Adair, Linda S
IR  - Assimes TL
FIR - Assimes, Themistocles L
IR  - Aung T
FIR - Aung, Tin
IR  - Cai Q
FIR - Cai, Qiuyin
IR  - Chang LC
FIR - Chang, Li-Ching
IR  - Chen CH
FIR - Chen, Chien-Hsiun
IR  - Chien LH
FIR - Chien, Li-Hsin
IR  - Chuang LM
FIR - Chuang, Lee-Ming
IR  - Chuang SC
FIR - Chuang, Shu-Chun
IR  - Du S
FIR - Du, Shufa
IR  - Fann CSJ
FIR - Fann, Cathy S J
IR  - Feranil AB
FIR - Feranil, Alan B
IR  - Friedlander Y
FIR - Friedlander, Yechiel
IR  - Gordon-Larsen P
FIR - Gordon-Larsen, Penny
IR  - Gu D
FIR - Gu, Dongfeng
IR  - Gui L
FIR - Gui, Lixuan
IR  - Guo Z
FIR - Guo, Zhirong
IR  - Heng CK
FIR - Heng, Chew-Kiat
IR  - Hixson J
FIR - Hixson, James
IR  - Hou X
FIR - Hou, Xuhong
IR  - Hsiung CA
FIR - Hsiung, Chao Agnes
IR  - Hu Y
FIR - Hu, Yao
IR  - Hwang MY
FIR - Hwang, Mi Yeong
IR  - Hwu CM
FIR - Hwu, Chii-Min
IR  - Isono M
FIR - Isono, Masato
IR  - Juang JJ
FIR - Juang, Jyh-Ming Jimmy
IR  - Khor CC
FIR - Khor, Chiea-Chuen
IR  - Kim YK
FIR - Kim, Yun Kyoung
IR  - Koh WP
FIR - Koh, Woon-Puay
IR  - Kubo M
FIR - Kubo, Michiaki
IR  - Lee IT
FIR - Lee, I-Te
IR  - Lee SJ
FIR - Lee, Sun-Ju
IR  - Liang KW
FIR - Liang, Kae-Woei
IR  - Lim B
FIR - Lim, Blanche
IR  - Lim SH
FIR - Lim, Sing-Hui
IR  - Liu J
FIR - Liu, Jianjun
IR  - Nabika T
FIR - Nabika, Toru
IR  - Pan WH
FIR - Pan, Wen-Harn
IR  - Peng H
FIR - Peng, Hao
IR  - Quertermous T
FIR - Quertermous, Thomas
IR  - Sabanayagam C
FIR - Sabanayagam, Charumathi
IR  - Shi J
FIR - Shi, Jinxiu
IR  - Sun L
FIR - Sun, Liang
IR  - Tan PC
FIR - Tan, Pok Chien
IR  - Tan SP
FIR - Tan, Shu-Pei
IR  - Taylor KD
FIR - Taylor, Kent D
IR  - Teo YY
FIR - Teo, Yik-Ying
IR  - Toh SA
FIR - Toh, Sue-Anne
IR  - Tsunoda T
FIR - Tsunoda, Tatsuhiko
IR  - van Dam RM
FIR - van Dam, Rob M
IR  - Wang A
FIR - Wang, Aili
IR  - Wang F
FIR - Wang, Feijie
IR  - Wang J
FIR - Wang, Jie
IR  - Wei WB
FIR - Wei, Wen Bin
IR  - Xiang YB
FIR - Xiang, Yong-Bing
IR  - Yao J
FIR - Yao, Jie
IR  - Yuan JM
FIR - Yuan, Jian-Min
IR  - Zhang R
FIR - Zhang, Rong
IR  - Zhao W
FIR - Zhao, Wanting
IR  - Rich SS
FIR - Rich, Stephen S
IR  - Wang TD
FIR - Wang, Tzung-Dau
IR  - Wu T
FIR - Wu, Tangchun
IR  - Lin X
FIR - Lin, Xu
IR  - Han BG
FIR - Han, Bok-Ghee
IR  - Tanaka T
FIR - Tanaka, Toshihiro
IR  - Cho YS
FIR - Cho, Yoon Shin
IR  - Katsuya T
FIR - Katsuya, Tomohiro
IR  - Jia W
FIR - Jia, Weiping
IR  - Jee SH
FIR - Jee, Sun-Ha
IR  - Chen YT
FIR - Chen, Yuan-Tsong
IR  - Kato N
FIR - Kato, Norihiro
IR  - Jonas JB
FIR - Jonas, Jost B
IR  - Shu XO
FIR - Shu, Xiao-Ou
IR  - He J
FIR - He, Jiang
IR  - Zheng W
FIR - Zheng, Wei
IR  - Huang W
FIR - Huang, Wei
IR  - Kim BJ
FIR - Kim, Bong-Jo
IR  - Tai ES
FIR - Tai, E-Shyong
IR  - Mohlke KL
FIR - Mohlke, Karen L
IR  - Sim X
FIR - Sim, Xueling
EDAT- 2017/09/28 06:00
MHDA- 2017/12/06 06:00
CRDT- 2017/09/28 06:00
PMCR- 2018/12/01 00:00
PHST- 2017/03/30 00:00 [received]
PHST- 2017/09/22 00:00 [accepted]
PHST- 2018/12/01 00:00 [pmc-release]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2017/09/28 06:00 [entrez]
AID - db17-0398 [pii]
AID - 10.2337/db17-0398 [doi]
PST - ppublish
SO  - Diabetes. 2017 Dec;66(12):3130-3141. doi: 10.2337/db17-0398. Epub 2017 Sep 26.

PMID- 28951388
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20180108
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 66
IP  - 12
DP  - 2017 Dec
TI  - Retinal Microperimetry: A New Tool for Identifying Patients With Type 2 Diabetes 
      at Risk for Developing Alzheimer Disease.
PG  - 3098-3104
LID - 10.2337/db17-0382 [doi]
AB  - Type 2 diabetes is associated with a high risk of cognitive impairment and
      dementia. Therefore, strategies are needed to identify patients who are at risk
      for dementia. Given that the retina is a brain-derived tissue, it may provide a
      noninvasive way to examine brain pathology. The aims of this study were to
      evaluate whether retinal sensitivity 1) correlates with the specific parameters
      of brain imaging related to cognitive impairment and 2) discriminates patients
      with diabetes with mild cognitive impairment (MCI) from those with normal
      cognition and those with Alzheimer disease (AD). For this purpose, a prospective,
      nested case-control study was performed and included 35 patients with type 2
      diabetes without cognitive impairment, 35 with MCI, and 35 with AD. Retinal
      sensitivity was assessed by Macular Integrity Assessment microperimetry, and a
      neuropsychological evaluation was performed. Brain neurodegeneration was assessed
      by MRI and fludeoxyglucose-18 positron emission tomography ((18)FDG-PET). A
      significant correlation was found between retinal sensitivity and the MRI and
      (18)FDG-PET parameters related to brain neurodegeneration. Retinal sensitivity
      was related to cognitive status (normocognitive > MCI > AD; P < 0.0001). Our
      results suggest that retinal sensitivity assessed by microperimetry is related to
      brain neurodegeneration and could be a useful biomarker for identifying patients 
      with type 2 diabetes who are at risk for developing AD.
CI  - (c) 2017 by the American Diabetes Association.
FAU - Ciudin, Andreea
AU  - Ciudin A
AD  - Institut de Recerca Vall d'Hebron, Universitat Autonoma de Barcelona (VHIR-UAB), 
      Barcelona, Spain.
AD  - CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Simo-Servat, Olga
AU  - Simo-Servat O
AD  - Institut de Recerca Vall d'Hebron, Universitat Autonoma de Barcelona (VHIR-UAB), 
      Barcelona, Spain.
AD  - CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Hernandez, Cristina
AU  - Hernandez C
AD  - Institut de Recerca Vall d'Hebron, Universitat Autonoma de Barcelona (VHIR-UAB), 
      Barcelona, Spain.
AD  - CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Arcos, Gabriel
AU  - Arcos G
AD  - Department of Ophthalmology, Hospital San Rafael, Barcelona, Spain.
FAU - Diego, Susana
AU  - Diego S
AD  - Fundacio ACE, Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain.
FAU - Sanabria, Angela
AU  - Sanabria A
AD  - Fundacio ACE, Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain.
FAU - Sotolongo, Oscar
AU  - Sotolongo O
AD  - Fundacio ACE, Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain.
FAU - Hernandez, Isabel
AU  - Hernandez I
AD  - Fundacio ACE, Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain.
FAU - Boada, Merce
AU  - Boada M
AD  - Fundacio ACE, Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain.
FAU - Simo, Rafael
AU  - Simo R
AUID- ORCID: 0000-0003-0475-3096
AD  - Institut de Recerca Vall d'Hebron, Universitat Autonoma de Barcelona (VHIR-UAB), 
      Barcelona, Spain rafael.simo@vhir.org.
AD  - CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT02360527
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170926
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*etiology
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Positron-Emission Tomography
MH  - Prospective Studies
MH  - *Visual Field Tests
EDAT- 2017/09/28 06:00
MHDA- 2017/12/06 06:00
CRDT- 2017/09/28 06:00
PHST- 2017/03/27 00:00 [received]
PHST- 2017/09/21 00:00 [accepted]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2017/09/28 06:00 [entrez]
AID - db17-0382 [pii]
AID - 10.2337/db17-0382 [doi]
PST - ppublish
SO  - Diabetes. 2017 Dec;66(12):3098-3104. doi: 10.2337/db17-0382. Epub 2017 Sep 26.

PMID- 28935628
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20180108
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 66
IP  - 12
DP  - 2017 Dec
TI  - Effect of Exercise-Induced Lactate Elevation on Brain Lactate Levels During
      Hypoglycemia in Patients With Type 1 Diabetes and Impaired Awareness of
      Hypoglycemia.
PG  - 3105-3110
LID - 10.2337/db17-0794 [doi]
AB  - Since altered brain lactate handling has been implicated in the development of
      impaired awareness of hypoglycemia (IAH) in type 1 diabetes, the capacity to
      transport lactate into the brain during hypoglycemia may be relevant in its
      pathogenesis. High-intensity interval training (HIIT) increases plasma lactate
      levels. We compared the effect of HIIT-induced hyperlacticacidemia on brain
      lactate during hypoglycemia between 1) patients with type 1 diabetes and IAH, 2) 
      patients with type 1 diabetes and normal awareness of hypoglycemia, and 3)
      healthy participants without diabetes (n = 6 per group). All participants
      underwent a hypoglycemic (2.8 mmol/L) clamp after performing a bout of HIIT on a 
      cycle ergometer. Before HIIT (baseline) and during hypoglycemia, brain lactate
      levels were determined continuously with J-difference-editing (1)H-MRS, and time 
      curves were analyzed using nonlinear mixed-effects modeling. At the beginning of 
      hypoglycemia (after HIIT), brain lactate levels were elevated in all groups but
      most pronounced in patients with IAH. During hypoglycemia, brain lactate
      decreased approximately 30% below baseline in patients with IAH but returned to
      baseline levels and remained there in the other two groups. Our results support
      the concept of enhanced lactate transport as well as increased lactate oxidation 
      in patients with type 1 diabetes and IAH.
CI  - (c) 2017 by the American Diabetes Association.
FAU - Wiegers, Evita C
AU  - Wiegers EC
AD  - Department of Radiology and Nuclear Medicine, Radboud University Medical Center, 
      Nijmegen, the Netherlands.
FAU - Rooijackers, Hanne M
AU  - Rooijackers HM
AUID- ORCID: 0000-0003-3829-4246
AD  - Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the
      Netherlands hanne.rooijackers@radboudumc.nl.
FAU - Tack, Cees J
AU  - Tack CJ
AD  - Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - Groenewoud, Hans J M M
AU  - Groenewoud HJMM
AD  - Department for Health Evidence, Radboud University Medical Center, Nijmegen, the 
      Netherlands.
FAU - Heerschap, Arend
AU  - Heerschap A
AD  - Department of Radiology and Nuclear Medicine, Radboud University Medical Center, 
      Nijmegen, the Netherlands.
FAU - de Galan, Bastiaan E
AU  - de Galan BE
AD  - Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - van der Graaf, Marinette
AU  - van der Graaf M
AD  - Department of Radiology and Nuclear Medicine, Radboud University Medical Center, 
      Nijmegen, the Netherlands.
AD  - Department of Pediatrics, Radboud University Medical Center, Nijmegen, the
      Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT02308293
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170921
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 33X04XA5AT (Lactic Acid)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Awareness
MH  - Brain/*metabolism
MH  - Diabetes Mellitus, Type 1/*metabolism
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Hypoglycemia/*metabolism
MH  - Lactic Acid/*metabolism
MH  - Male
MH  - Young Adult
EDAT- 2017/09/25 06:00
MHDA- 2017/12/06 06:00
CRDT- 2017/09/23 06:00
PHST- 2017/07/06 00:00 [received]
PHST- 2017/09/15 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2017/09/23 06:00 [entrez]
AID - db17-0794 [pii]
AID - 10.2337/db17-0794 [doi]
PST - ppublish
SO  - Diabetes. 2017 Dec;66(12):3105-3110. doi: 10.2337/db17-0794. Epub 2017 Sep 21.

PMID- 28957454
OWN - NLM
STAT- MEDLINE
DCOM- 20171013
LR  - 20180813
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 102
IP  - 9
DP  - 2017 Sep 1
TI  - The Effect of Improved Serum 25-Hydroxyvitamin D Status on Glycemic Control in
      Diabetic Patients: A Meta-Analysis.
PG  - 3097-3110
LID - 10.1210/jc.2017-01024 [doi]
AB  - Background: Type 2 diabetes is a global health concern, with an increased
      prevalence and high cost of treatment. Objective: The aim of this systematic
      review and meta-analysis was to determine the effect of vitamin D supplementation
      and improved vitamin D status on glycemia and insulin resistance in type 2
      diabetic patients. Data Source: We searched PUBMED/Medline, Cumulative Index to
      Nursing and Allied Health, and Cochrane Library (until January 2017). Study
      Selection: Prospective clinical trials were selected evaluating the impact of
      vitamin D supplementation on glycosylated hemoglobin (HbA1c), serum fasting
      plasma glucose (FPG), and homeostatic model assessment of insulin resistance
      (HOMA-IR) in diabetic patients. Data Extraction and Synthesis: We used a
      random-effects model to synthesize quantitative data, followed by a leave-one-out
      method for sensitivity analysis. The systematic review registration was
      CRD42017059555. From a total of 844 entries identified via literature search, 24 
      controlled trials (1528 individuals diagnosed with type 2 diabetes) were
      included. The meta-analysis indicated a significant reduction in HbA1c [mean
      difference: -0.30%; 95% confidence interval (CI): -0.45 to -0.15, P < 0.001], FPG
      [mean difference: -4.9 mg/dL (-0.27 mmol/L); 95% CI: -8.1 to -1.6 (-0.45 to -0.09
      mmol/L), P = 0.003], and HOMA-IR (mean difference: -0.66; 95% CI: -1.06 to -0.26,
      P = 0.001) following vitamin D supplementation and significant increase in serum 
      25-hydroxyvitamin D levels [overall increase of 17 +/- 2.4 ng/mL (42 +/- 6
      nmol/L)]. Conclusions: Vitamin D supplementation, a minimum dose of 100 microg/d 
      (4000 IU/d), may significantly reduce serum FPG, HbA1c, and HOMA-IR index, and
      helps to control glycemic response and improve insulin sensitivity in type 2
      diabetic patients.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Mirhosseini, Naghmeh
AU  - Mirhosseini N
AD  - Pure North S'Energy Foundation, Calgary, Alberta T2R 0C5, Canada.
FAU - Vatanparast, Hassanali
AU  - Vatanparast H
AD  - College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon,
      Saskatchewan S7N 5A2, Canada.
FAU - Mazidi, Mohsen
AU  - Mazidi M
AD  - Key State Laboratory of Molecular Developmental Biology, Institute of Genetics
      and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China.
AD  - Institute of Genetics and Developmental Biology, International College,
      University of Chinese Academy of Sciences, Beijing 100101, China.
FAU - Kimball, Samantha M
AU  - Kimball SM
AD  - Pure North S'Energy Foundation, Calgary, Alberta T2R 0C5, Canada.
AD  - St. Mary's University, Calgary, Alberta T2X 1Z4, Canada.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 1406-16-2 (Vitamin D)
RN  - A288AR3C9H (25-hydroxyvitamin D)
SB  - AIM
SB  - IM
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 2/*blood/complications/diet therapy/drug therapy
MH  - Dietary Supplements
MH  - Glycated Hemoglobin A/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Vitamin D/administration & dosage/*analogs & derivatives/blood
MH  - Vitamin D Deficiency/blood/complications/*diet therapy
EDAT- 2017/09/29 06:00
MHDA- 2017/10/14 06:00
CRDT- 2017/09/29 06:00
PHST- 2017/05/04 00:00 [received]
PHST- 2017/06/28 00:00 [accepted]
PHST- 2017/09/29 06:00 [entrez]
PHST- 2017/09/29 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
AID - 3920535 [pii]
AID - 10.1210/jc.2017-01024 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2017 Sep 1;102(9):3097-3110. doi: 10.1210/jc.2017-01024.

PMID- 28945872
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20180518
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 102
IP  - 11
DP  - 2017 Nov 1
TI  - Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese
      Patients With Type 2 Diabetes.
PG  - 4109-4116
LID - 10.1210/jc.2017-00913 [doi]
AB  - Context: Lung impairment is a new target for late diabetic complications.
      Biomarkers that could help identify patients requiring functional respiratory
      tests have not been reported. Objective: Our aim was to examine whether serum
      surfactant protein D (SP-D) and A (SP-A) could be useful biomarkers of lung
      damage in obese patients with type 2 diabetes (T2D) without known lung disease.
      Design and Setting: A case-control study conducted in an ambulatory obesity unit.
      Patients: Forty-nine obese patients with T2D and 98 subjects without diabetes
      matched by age, sex, body mass index, and waist circumference were included.
      Interventions: Serum SP-D and SP-A levels were measured using enzyme-linked
      immunosorbent assay. Forced spirometry and static pulmonary volume were assessed.
      Results: Patients with T2D exhibited higher serum SP-D concentrations than
      control subjects (P = 0.006). No differences in serum SP-A concentrations were
      observed. There was an inverse association between forced expiratory volume in 1 
      second (FEV1) and serum SP-D (r = -0.265; P = 0.029), as well as a significant
      positive relationship between SP-D concentration and residual volume (r = 0.293; 
      P = 0.043). From receiver operating characteristic analysis, the best SP-D cutoff
      to identify a FEV1 <80% of predicted was 132.3 ng/mL (area under the curve,
      0.725; sensitivity, 77.7%; specificity, 69.4%). Stepwise multivariate regression 
      analysis showed that serum SP-D concentration >/=132.3 ng/mL was independently
      associated with a FEV1 <80% of predicted (R2 = 0.406). Only the existence of T2D 
      contributed independently to serum SD-P variance among all subjects (R2 = 0.138).
      Conclusions: Serum SP-D concentration can be a useful biomarker for detecting
      lung impairment in obese patients with T2D.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Lopez-Cano, Carolina
AU  - Lopez-Cano C
AD  - Endocrinology and Nutrition Department, Hospital Universitari Arnau de Vilanova, 
      Institut de Recerca Biomedica de Lleida, Universitat de Lleida, 25198 Lleida,
      Catalonia, Spain.
FAU - Lecube, Albert
AU  - Lecube A
AD  - Endocrinology and Nutrition Department, Hospital Universitari Arnau de Vilanova, 
      Institut de Recerca Biomedica de Lleida, Universitat de Lleida, 25198 Lleida,
      Catalonia, Spain.
AD  - Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas
      Asociadas, Instituto de Salud Carlos III, 28029 Madrid, Spain.
FAU - Garcia-Ramirez, Marta
AU  - Garcia-Ramirez M
AD  - Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas
      Asociadas, Instituto de Salud Carlos III, 28029 Madrid, Spain.
AD  - Endocrinology and Nutrition Department, Hospital Universitari Vall d'Hebron,
      Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca,
      Universitat Autonoma de Barcelona, 08035 Barcelona, Catalonia, Spain.
FAU - Munoz, Xavier
AU  - Munoz X
AD  - Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron
      Institut de Recerca, 08035 Barcelona, Catalonia, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias, Instituto
      de Salud Carlos III, 28029 Madrid, Spain.
FAU - Sanchez, Enric
AU  - Sanchez E
AD  - Endocrinology and Nutrition Department, Hospital Universitari Arnau de Vilanova, 
      Institut de Recerca Biomedica de Lleida, Universitat de Lleida, 25198 Lleida,
      Catalonia, Spain.
FAU - Seminario, Asuncion
AU  - Seminario A
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias, Instituto
      de Salud Carlos III, 28029 Madrid, Spain.
AD  - Respiratory Department, Hospital Universitari Arnau de Vilanova-Santa Maria,
      Institut de Recerca Biomedica de Lleida, Universitat de Lleida, 25198 Lleida,
      Catalonia, Spain.
FAU - Hernandez, Marta
AU  - Hernandez M
AD  - Endocrinology and Nutrition Department, Hospital Universitari Arnau de Vilanova, 
      Institut de Recerca Biomedica de Lleida, Universitat de Lleida, 25198 Lleida,
      Catalonia, Spain.
FAU - Ciudin, Andreea
AU  - Ciudin A
AD  - Endocrinology and Nutrition Department, Hospital Universitari Vall d'Hebron,
      Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca,
      Universitat Autonoma de Barcelona, 08035 Barcelona, Catalonia, Spain.
FAU - Gutierrez, Liliana
AU  - Gutierrez L
AD  - Endocrinology and Nutrition Department, Hospital Universitari Arnau de Vilanova, 
      Institut de Recerca Biomedica de Lleida, Universitat de Lleida, 25198 Lleida,
      Catalonia, Spain.
FAU - Hernandez, Cristina
AU  - Hernandez C
AD  - Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas
      Asociadas, Instituto de Salud Carlos III, 28029 Madrid, Spain.
AD  - Endocrinology and Nutrition Department, Hospital Universitari Vall d'Hebron,
      Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca,
      Universitat Autonoma de Barcelona, 08035 Barcelona, Catalonia, Spain.
FAU - Simo, Rafael
AU  - Simo R
AD  - Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas
      Asociadas, Instituto de Salud Carlos III, 28029 Madrid, Spain.
AD  - Endocrinology and Nutrition Department, Hospital Universitari Vall d'Hebron,
      Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca,
      Universitat Autonoma de Barcelona, 08035 Barcelona, Catalonia, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Biomarkers)
RN  - 0 (Pulmonary Surfactant-Associated Protein D)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Biomarkers/*blood
MH  - Case-Control Studies
MH  - Diabetes Complications/blood/diagnosis
MH  - Diabetes Mellitus, Type 2/*blood/complications
MH  - Female
MH  - Humans
MH  - Lung/physiopathology
MH  - Lung Diseases/blood/complications/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Obesity/*blood/complications
MH  - Pulmonary Surfactant-Associated Protein D/*blood
MH  - Respiratory Function Tests
MH  - Sensitivity and Specificity
MH  - Spirometry
EDAT- 2017/09/26 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/09/26 06:00
PHST- 2017/04/18 00:00 [received]
PHST- 2017/09/08 00:00 [accepted]
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
AID - 4157553 [pii]
AID - 10.1210/jc.2017-00913 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2017 Nov 1;102(11):4109-4116. doi:
      10.1210/jc.2017-00913.

PMID- 28938465
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180518
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 102
IP  - 10
DP  - 2017 Oct 1
TI  - Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1
      Diabetes.
PG  - 3814-3821
LID - 10.1210/jc.2017-00892 [doi]
AB  - Context: Insulin resistance could increase insulin requirements in type 1
      diabetes (T1D). Current insulin immunoassays do not detect insulin analogs.
      Kinase insulin receptor (IR) activation (KIRA) bioassays specific for human IR
      isoforms A (IR-A) and B (IR-B) permit assessment of all circulating insulin
      bioactivity. We studied whether IR-A and IR-B KIRA assays are related to direct
      measures of insulin sensitivity or insulin doses in T1D. Design: We evaluated 31 
      adult patients with T1D (age 45.7 +/- 1.6 years, body mass index 28.8 +/- 0.7
      kg/m2). Serum IR-A and IR-B bioactivities were measured by KIRA bioassays.
      Insulin sensitivity of glucose production (Ra) was measured by the euglycemic
      hyperinsulinemic clamp technique in which a low insulin dose (0.4 mU/kg/min for
      240 minutes) was combined with D-[3-3H] glucose infusion to measure rates of Ra
      and utilization and insulin action on antilipolysis from suppression of serum
      free fatty acids. Results: Baseline circulating IR-A bioactivity was 53 +/- 7
      pmol/L, and IR-B bioactivity was 81 +/- 11 pmol/L. Compared with baseline,
      insulin infusion significantly increased IR-A (P < 0.001) and IR-B (P < 0.001)
      bioactivities. Fasting IR-A and IR-B bioactivities were positively related to
      endogenous Ra (r = 0.44, P = 0.01 and r = 0.38, P < 0.05). Fasting IR-A (r =
      0.43, P = 0.02) and IR-B (r = 0.47, P = 0.01) bioactivities were significantly
      correlated with insulin requirements and glycosylated hemoglobin (IR-A: r = 0.52,
      P = 0.002; IR-B: r = 0.48, P = 0.006). Conclusions: Circulating IR-A and IR-B
      bioactivities are associated with insulin resistance, high insulin requirements, 
      and poor glycemic control in T1D. Measurement of IR bioactivity by KIRA assays
      provides a tool to assess the amount of biologically active insulin in groups of 
      T1D patients treated with insulin analogs.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Janssen, Joseph A M J L
AU  - Janssen JAMJL
AD  - Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 CE
      Rotterdam, The Netherlands.
FAU - Llaurado, Gemma
AU  - Llaurado G
AD  - Minerva Foundation Institute for Medical Research, 00290 Helsinki, Finland.
AD  - Department of Endocrinology and Nutrition, Hospital del Mar, 08003 Barcelona,
      Spain.
AD  - Endocrinology and Nutrition Section, Joan XXIII University Hospital, IISPV Pere
      Virgili Health Research Institute, Rovira i Virgili University, 43005 Tarragona, 
      Spain.
AD  - CIBER Diabetes y Enfermedades Metabolicas Asociadas, Instituto de Salud Carlos
      III, 28029 Madrid, Spain.
FAU - Varewijck, Aimee J
AU  - Varewijck AJ
AD  - Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 CE
      Rotterdam, The Netherlands.
FAU - Groop, Per-Henrik
AU  - Groop PH
AD  - Folkhalsan Research Centre, Folkhalsan Institute of Genetics, Biomedicum
      Helsinki, 00014 Helsinki, Finland.
FAU - Forsblom, Carol
AU  - Forsblom C
AD  - Folkhalsan Research Centre, Folkhalsan Institute of Genetics, Biomedicum
      Helsinki, 00014 Helsinki, Finland.
FAU - Fernandez-Veledo, Sonia
AU  - Fernandez-Veledo S
AD  - Endocrinology and Nutrition Section, Joan XXIII University Hospital, IISPV Pere
      Virgili Health Research Institute, Rovira i Virgili University, 43005 Tarragona, 
      Spain.
AD  - CIBER Diabetes y Enfermedades Metabolicas Asociadas, Instituto de Salud Carlos
      III, 28029 Madrid, Spain.
FAU - van den Dungen, Elisabeth S R
AU  - van den Dungen ESR
AD  - Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 CE
      Rotterdam, The Netherlands.
FAU - Vendrell, Joan
AU  - Vendrell J
AD  - Endocrinology and Nutrition Section, Joan XXIII University Hospital, IISPV Pere
      Virgili Health Research Institute, Rovira i Virgili University, 43005 Tarragona, 
      Spain.
AD  - CIBER Diabetes y Enfermedades Metabolicas Asociadas, Instituto de Salud Carlos
      III, 28029 Madrid, Spain.
FAU - Hofland, Leo J
AU  - Hofland LJ
AD  - Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 CE
      Rotterdam, The Netherlands.
FAU - Yki-Jarvinen, Hannele
AU  - Yki-Jarvinen H
AD  - Minerva Foundation Institute for Medical Research, 00290 Helsinki, Finland.
AD  - Department of Medicine, University of Helsinki, 00290 Helsinki, Finland.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Biological Assay/*methods
MH  - Blood Chemical Analysis/*methods
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Type 1/blood/*drug therapy
MH  - Drug Dosage Calculations
MH  - Female
MH  - Glucose Clamp Technique
MH  - Glycated Hemoglobin A/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin/*administration & dosage/analysis/*blood
MH  - *Insulin Resistance
MH  - Lipolysis/drug effects
MH  - Male
MH  - Middle Aged
EDAT- 2017/09/25 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/09/23 06:00
PHST- 2017/04/14 00:00 [received]
PHST- 2017/08/09 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
PHST- 2017/09/23 06:00 [entrez]
AID - 4080739 [pii]
AID - 10.1210/jc.2017-00892 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2017 Oct 1;102(10):3814-3821. doi:
      10.1210/jc.2017-00892.

PMID- 28938447
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180518
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 102
IP  - 10
DP  - 2017 Oct 1
TI  - Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of
      Women With Polycystic Ovary Syndrome.
PG  - 3848-3857
LID - 10.1210/jc.2017-01354 [doi]
AB  - Objective: Polycystic ovary syndrome (PCOS) is associated with insulin resistance
      and obesity. Prospective population-based data regarding development and possible
      predictors of type 2 diabetes (T2D) in PCOS are limited. Design: National Patient
      Register-based study. Methods: Patients with PCOS [PCOS Denmark and embedded
      cohort, PCOS Odense University Hospital (OUH)] and a control population with no
      previous diagnosis of T2D. PCOS OUH (N = 1,162) included premenopausal women with
      PCOS and standardized clinical and biochemical examination. PCOS Denmark (N =
      18,477) included women with PCOS in the Danish National Patient Register. Three
      age-matched controls were included per patient (N = 54,680). Main outcome: T2D
      events according to diagnosis codes and filled medicine prescriptions. Results:
      The median (quartiles) follow-up was 11.1 (6.9 to 16.0) years. The hazard ratio
      (HR) with 95% confidence interval (CI) for development of T2D in PCOS Denmark was
      HR = 4.0 (95% CI, 3.7 to 4.3; P < 0.001), and the total event rate of T2D was 8.0
      per 1000 person years in PCOS Denmark vs 2.0 per 1000 person years in controls (P
      < 0.001). The median age at diagnosis of T2D was 31 (26 to 37) years in PCOS
      Denmark vs 35 (27 to 44) years in controls (P < 0.001). In multiple regression
      analyses, body mass index, glycated hemoglobin, fasting blood glucose, 2-hour
      blood glucose, homeostasis model assessment of insulin resistance, and
      triglycerides were positively associated with development of T2D, whereas higher 
      number of births was negatively associated with development of T2D. Conclusion:
      The event rate of T2D was higher in PCOS compared with controls, and T2D was
      diagnosed at a younger age.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Rubin, Katrine Hass
AU  - Rubin KH
AD  - OPEN-Odense Patient Data Explorative Network, Institute of Clinical Research,
      University of Southern Denmark, 5000 Odense C, Denmark.
FAU - Glintborg, Dorte
AU  - Glintborg D
AD  - Department of Endocrinology, Odense University Hospital, 5000 Odense C, Denmark.
FAU - Nybo, Mads
AU  - Nybo M
AD  - Department of Clinical Biochemistry and Pharmacology, Odense University Hospital,
      5000 Odense C, Denmark.
FAU - Abrahamsen, Bo
AU  - Abrahamsen B
AD  - OPEN-Odense Patient Data Explorative Network, Institute of Clinical Research,
      University of Southern Denmark, 5000 Odense C, Denmark.
AD  - Department of Medicine, Holbaek Hospital, 4300 Holbaek, Denmark.
FAU - Andersen, Marianne
AU  - Andersen M
AD  - Department of Endocrinology, Odense University Hospital, 5000 Odense C, Denmark.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
CIN - J Clin Endocrinol Metab. 2018 Jan 1;103(1):360-361. PMID: 29126227
CIN - J Clin Endocrinol Metab. 2018 Jan 1;103(1):362-363. PMID: 29126200
MH  - Adolescent
MH  - Adult
MH  - Case-Control Studies
MH  - Child
MH  - Denmark/epidemiology
MH  - Diabetes Mellitus, Type 2/*epidemiology/*etiology/pathology
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Polycystic Ovary Syndrome/*complications/*epidemiology
MH  - Registries
MH  - Risk Factors
MH  - Young Adult
EDAT- 2017/09/25 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/09/23 06:00
PHST- 2017/06/14 00:00 [received]
PHST- 2017/08/11 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
PHST- 2017/09/23 06:00 [entrez]
AID - 4096783 [pii]
AID - 10.1210/jc.2017-01354 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2017 Oct 1;102(10):3848-3857. doi:
      10.1210/jc.2017-01354.

PMID- 28938439
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20180518
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 102
IP  - 11
DP  - 2017 Nov 1
TI  - Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1
      Secretion in Patients With Type 2 Diabetes.
PG  - 4153-4162
LID - 10.1210/jc.2017-01091 [doi]
AB  - Context: Despite a position as the first-line pharmacotherapy in type 2 diabetes,
      the glucose-lowering mechanisms of metformin remain to be fully clarified.
      Gut-derived modes of action, including suppression of bile acid reabsorption and 
      a resulting increase in glucagon-like peptide-1 (GLP-1) secretion, have been
      proposed. Objective: The aim of this study was to assess the GLP-1 secretory and 
      glucometabolic effects of endogenously released bile, with and without
      concomitant single-dose administration of metformin in patients with type 2
      diabetes. Design: Randomized, placebo-controlled, and double-blinded crossover
      study. Setting: This study was conducted at Center for Diabetes Research,
      Gentofte Hospital, Denmark. Patients: Fifteen metformin-treated patients with
      type 2 diabetes; all participants completed the study. Interventions: Four
      experimental study days in randomized order with administration of either 1500 mg
      metformin or placebo in combination with intravenous infusion of cholecystokinin 
      (0.4 pmol x kg-1 x min-1) or saline. Main Outcome Measure: Plasma GLP-1
      excursions as measured by baseline-subtracted area under the curve. Results:
      Single-dose metformin further enhanced bile acid-mediated induction of GLP-1
      secretion (P = 0.02), whereas metformin alone did not increase plasma GLP-1
      concentrations compared with placebo (P = 0.17). Metformin, both with (P = 0.02) 
      and without (P = 0.02) concomitant cholecystokinin-induced gallbladder emptying, 
      elicited reduced plasma glucose excursions compared with placebo. No
      GLP-1-mediated induction of insulin secretion or suppression of glucagon was
      observed. Conclusions: Metformin elicited an enhancement of the GLP-1 response to
      cholecystokinin-induced gallbladder emptying in patients with type 2 diabetes,
      whereas no derived effects on insulin or glucagon secretion were evident in this 
      acute setting.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Bronden, Andreas
AU  - Bronden A
AD  - Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, 2900
      Hellerup, Denmark.
FAU - Alber, Anders
AU  - Alber A
AD  - Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, 2900
      Hellerup, Denmark.
FAU - Rohde, Ulrich
AU  - Rohde U
AD  - Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, 2900
      Hellerup, Denmark.
FAU - Rehfeld, Jens F
AU  - Rehfeld JF
AD  - Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen,
      2100 Copenhagen O, Denmark.
FAU - Holst, Jens J
AU  - Holst JJ
AD  - Department of Biomedical Sciences, Faculty of Health and Medical Sciences,
      University of Copenhagen, 2200 Copenhagen N, Denmark.
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark.
FAU - Vilsboll, Tina
AU  - Vilsboll T
AD  - Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, 2900
      Hellerup, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, 2200 Copenhagen N, Denmark.
AD  - Steno Diabetes Center Copenhagen, University of Copenhagen, 2820 Gentofte,
      Denmark.
FAU - Knop, Filip K
AU  - Knop FK
AD  - Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, 2900
      Hellerup, Denmark.
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, 2200 Copenhagen N, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT02497313
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Blood Glucose)
RN  - 0 (Placebos)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9011-97-6 (Cholecystokinin)
RN  - 9100L32L2N (Metformin)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Bile Acids and Salts/*pharmacology
MH  - Blood Glucose/metabolism
MH  - Cholecystokinin/pharmacology
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Gallbladder Emptying/drug effects/physiology
MH  - Glucagon-Like Peptide 1/*secretion
MH  - Humans
MH  - Male
MH  - Metformin/*administration & dosage
MH  - Middle Aged
MH  - Placebos
EDAT- 2017/09/25 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/09/23 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2017/08/15 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/09/23 06:00 [entrez]
AID - 4084559 [pii]
AID - 10.1210/jc.2017-01091 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2017 Nov 1;102(11):4153-4162. doi:
      10.1210/jc.2017-01091.

PMID- 28938433
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180518
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 102
IP  - 10
DP  - 2017 Oct 1
TI  - Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management.
PG  - 3621-3634
LID - 10.1210/jc.2017-00042 [doi]
AB  - Context: Both type 2 diabetes (T2D) and osteoporosis are affected by aging and
      quite often coexist. Furthermore, the fracture risk in patients with T2D is
      increased. The aim of this article is to review updated information on
      osteoporosis and fracture risk in patients with T2D, to discuss the effects of
      diabetes treatment on bone metabolism, as well as the effect of antiosteoporotic 
      medications on the incidence and control of T2D, and to provide a personalized
      guide to the optimal management. Evidence Acquisition: A systematic literature
      search for human studies was conducted in three electronic databases (PubMed,
      Cochrane, and EMBASE) until March 2017. Regarding recommendations, we adopted the
      grading system introduced by the American College of Physicians. Evidence
      Synthesis: The results are presented in systematic tables. Healthy diet and
      physical exercise are very important for the prevention and treatment of both
      entities. Metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, and
      glucagon-like peptide-1 receptor agonists should be preferred for the treatment
      of T2D in these patients, whereas strict targets should be avoided for the fear
      of hypoglycemia, falls, and fractures. Insulin should be used with caution and
      with careful measures to avoid hypoglycemia. Thiazolidinediones and canagliflozin
      should be avoided, whereas other sodium-dependent glucose transporter 2
      inhibitors are less well-validated options. Insulin therapy is the preferred
      method for achieving glycemic control in hospitalized patients with T2D and
      fractures. The treatment and monitoring of osteoporosis should be continued
      without important amendments because of the presence of T2D. Conclusions:
      Patients with coexisting T2D and osteoporosis should be managed in an optimal way
      according to scientific evidence.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Paschou, Stavroula A
AU  - Paschou SA
AD  - Division of Endocrinology and Diabetes, Aghia Sophia Hospital, Medical School,
      National and Kapodistrian University of Athens, 11527 Athens, Greece.
FAU - Dede, Anastasia D
AU  - Dede AD
AD  - Department of Endocrinology and Diabetes, Chelsea and Westminster Hospital,
      London SW10 9NH, United Kingdom.
FAU - Anagnostis, Panagiotis G
AU  - Anagnostis PG
AD  - Unit of Reproductive Endocrinology, First Department of Obstetrics and
      Gynecology, Medical School, Aristotle University of Thessaloniki, 54124
      Thessaloniki, Greece.
FAU - Vryonidou, Andromachi
AU  - Vryonidou A
AD  - Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, 11526
      Athens, Greece.
FAU - Morganstein, Daniel
AU  - Morganstein D
AD  - Department of Endocrinology and Diabetes, Chelsea and Westminster Hospital,
      London SW10 9NH, United Kingdom.
FAU - Goulis, Dimitrios G
AU  - Goulis DG
AD  - Unit of Reproductive Endocrinology, First Department of Obstetrics and
      Gynecology, Medical School, Aristotle University of Thessaloniki, 54124
      Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Hypoglycemic Agents)
SB  - AIM
SB  - IM
MH  - Bone and Bones/drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/*complications/*therapy
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Osteoporosis/*complications/*therapy
MH  - Osteoporotic Fractures/etiology/prevention & control
MH  - *Practice Guidelines as Topic/standards
MH  - Risk Factors
EDAT- 2017/09/25 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/09/23 06:00
PHST- 2017/01/04 00:00 [received]
PHST- 2017/05/18 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
PHST- 2017/09/23 06:00 [entrez]
AID - 3882598 [pii]
AID - 10.1210/jc.2017-00042 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2017 Oct 1;102(10):3621-3634. doi:
      10.1210/jc.2017-00042.

PMID- 28938416
OWN - NLM
STAT- MEDLINE
DCOM- 20180626
LR  - 20180626
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 103
IP  - 1
DP  - 2018 Jan 1
TI  - Pancreatic Histopathology of Human Monogenic Diabetes Due to Causal Variants in
      KCNJ11, HNF1A, GATA6, and LMNA.
PG  - 35-45
LID - 10.1210/jc.2017-01159 [doi]
AB  - Context: Monogenic diabetes is thought to account for 2% of all diabetes cases,
      but most patients receive misdiagnoses of type 1 or type 2 diabetes. To date,
      little is known about the histopathological features of pancreata from patients
      with monogenic diabetes. Objective: Retrospective study of the JDRF Network for
      Pancreatic Organ Donors with Diabetes biorepository to identify possible cases of
      monogenic diabetes and to compare effects of genetic variants on pancreas
      histology. Methods: We selected cases of diabetes for genetic testing on the
      basis of criteria that included young age at diagnosis, low body mass index,
      negative autoantibody status, and/or detectable C-peptide level. Samples
      underwent next-generation-targeted sequencing of 140 diabetes/diabetes-related
      genes. Pancreas weight and histopathology were reviewed. Results: Forty-one of
      140 cases of diabetes met the clinical inclusion criteria, with 38 DNA samples
      available. Genetic variants of probable clinical significance were found in four 
      cases: one each in KCNJ11, HNF1A, GATA6, and LMNA. The KCNJ11 and HNF1A samples
      had significantly decreased pancreas weight and insulin mass similar to that of
      type 1 diabetes but had no insulitis. The GATA6 sample had severe pancreatic
      atrophy but with abundant beta cells and severe amyloidosis similar to type 2
      diabetes. The LMNA sample had preserved pancreas weight and insulin mass but
      abnormal islet architecture and exocrine fatty infiltrates. Conclusions: Four
      cases of diabetes had putative causal variants in monogenic diabetes genes. This 
      study provides further insight into the heterogeneous nature of monogenic
      diabetes cases that exhibited clinical and pathophysiological features that
      overlap with type 1/type 2 diabetes.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Sanyoura, May
AU  - Sanyoura M
AD  - Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, The
      University of Chicago, Chicago, Illinois.
FAU - Jacobsen, Laura
AU  - Jacobsen L
AD  - Department of Pediatrics, University of Florida, Gainesville, Florida.
FAU - Carmody, David
AU  - Carmody D
AD  - Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, The
      University of Chicago, Chicago, Illinois.
FAU - Del Gaudio, Daniela
AU  - Del Gaudio D
AD  - Department of Human Genetics, The University of Chicago, Chicago, Illinois.
FAU - Alkorta-Aranburu, Gorka
AU  - Alkorta-Aranburu G
AD  - Department of Human Genetics, The University of Chicago, Chicago, Illinois.
FAU - Arndt, Kelly
AU  - Arndt K
AD  - Department of Human Genetics, The University of Chicago, Chicago, Illinois.
FAU - Hu, Ying
AU  - Hu Y
AD  - Department of Human Genetics, The University of Chicago, Chicago, Illinois.
FAU - Kobiernicki, Frances
AU  - Kobiernicki F
AD  - Department of Human Genetics, The University of Chicago, Chicago, Illinois.
FAU - Kusmartseva, Irina
AU  - Kusmartseva I
AD  - Department of Pathology, Immunology and Laboratory Medicine, University of
      Florida, Gainesville, Florida.
FAU - Atkinson, Mark A
AU  - Atkinson MA
AD  - Department of Pathology, Immunology and Laboratory Medicine, University of
      Florida, Gainesville, Florida.
FAU - Philipson, Louis H
AU  - Philipson LH
AD  - Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, The
      University of Chicago, Chicago, Illinois.
FAU - Schatz, Desmond
AU  - Schatz D
AD  - Department of Pediatrics, University of Florida, Gainesville, Florida.
FAU - Campbell-Thompson, Martha
AU  - Campbell-Thompson M
AD  - Department of Pathology, Immunology and Laboratory Medicine, University of
      Florida, Gainesville, Florida.
FAU - Greeley, Siri Atma W
AU  - Greeley SAW
AD  - Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, The
      University of Chicago, Chicago, Illinois.
LA  - eng
GR  - K23 DK094866/DK/NIDDK NIH HHS/United States
GR  - P30 DK020595/DK/NIDDK NIH HHS/United States
GR  - R01 DK104942/DK/NIDDK NIH HHS/United States
GR  - UC4 DK104155/DK/NIDDK NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (GATA6 Transcription Factor)
RN  - 0 (GATA6 protein, human)
RN  - 0 (HNF1A protein, human)
RN  - 0 (Hepatocyte Nuclear Factor 1-alpha)
RN  - 0 (Kir6.2 channel)
RN  - 0 (LMNA protein, human)
RN  - 0 (Lamin Type A)
RN  - 0 (Potassium Channels, Inwardly Rectifying)
SB  - AIM
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Diabetes Mellitus/genetics/*pathology
MH  - Female
MH  - GATA6 Transcription Factor/*genetics
MH  - Genetic Testing
MH  - *Genetic Variation
MH  - Hepatocyte Nuclear Factor 1-alpha/*genetics
MH  - Humans
MH  - Lamin Type A/*genetics
MH  - Male
MH  - Pancreas/metabolism/*pathology
MH  - Potassium Channels, Inwardly Rectifying/*genetics
MH  - Prognosis
MH  - Retrospective Studies
PMC - PMC5761488
EDAT- 2017/09/25 06:00
MHDA- 2018/06/27 06:00
CRDT- 2017/09/23 06:00
PMCR- 2019/01/01 00:00
PHST- 2017/05/19 00:00 [received]
PHST- 2017/08/06 00:00 [accepted]
PHST- 2019/01/01 00:00 [pmc-release]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2018/06/27 06:00 [medline]
PHST- 2017/09/23 06:00 [entrez]
AID - 4082869 [pii]
AID - 10.1210/jc.2017-01159 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2018 Jan 1;103(1):35-45. doi: 10.1210/jc.2017-01159.

PMID- 28930514
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20180502
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 12
DP  - 2017 Sep 21
TI  - Weight and Metabolic Outcomes 12 Years after Gastric Bypass.
PG  - 1143-1155
LID - 10.1056/NEJMoa1700459 [doi]
AB  - BACKGROUND: Few long-term or controlled studies of bariatric surgery have been
      conducted to date. We report the 12-year follow-up results of an observational,
      prospective study of Roux-en-Y gastric bypass that was conducted in the United
      States. METHODS: A total of 1156 patients with severe obesity comprised three
      groups: 418 patients who sought and underwent Roux-en-Y gastric bypass (surgery
      group), 417 patients who sought but did not undergo surgery (primarily for
      insurance reasons) (nonsurgery group 1), and 321 patients who did not seek
      surgery (nonsurgery group 2). We performed clinical examinations at baseline and 
      at 2 years, 6 years, and 12 years to ascertain the presence of type 2 diabetes,
      hypertension, and dyslipidemia. RESULTS: The follow-up rate exceeded 90% at 12
      years. The adjusted mean change from baseline in body weight in the surgery group
      was -45.0 kg (95% confidence interval [CI], -47.2 to -42.9; mean percent change, 
      -35.0) at 2 years, -36.3 kg (95% CI, -39.0 to -33.5; mean percent change, -28.0) 
      at 6 years, and -35.0 kg (95% CI, -38.4 to -31.7; mean percent change, -26.9) at 
      12 years; the mean change at 12 years in nonsurgery group 1 was -2.9 kg (95% CI, 
      -6.9 to 1.0; mean percent change, -2.0), and the mean change at 12 years in
      nonsurgery group 2 was 0 kg (95% CI, -3.5 to 3.5; mean percent change, -0.9).
      Among the patients in the surgery group who had type 2 diabetes at baseline, type
      2 diabetes remitted in 66 of 88 patients (75%) at 2 years, in 54 of 87 patients
      (62%) at 6 years, and in 43 of 84 patients (51%) at 12 years. The odds ratio for 
      the incidence of type 2 diabetes at 12 years was 0.08 (95% CI, 0.03 to 0.24) for 
      the surgery group versus nonsurgery group 1 and 0.09 (95% CI, 0.03 to 0.29) for
      the surgery group versus nonsurgery group 2 (P<0.001 for both comparisons). The
      surgery group had higher remission rates and lower incidence rates of
      hypertension and dyslipidemia than did nonsurgery group 1 (P<0.05 for all
      comparisons). CONCLUSIONS: This study showed long-term durability of weight loss 
      and effective remission and prevention of type 2 diabetes, hypertension, and
      dyslipidemia after Roux-en-Y gastric bypass. (Funded by the National Institute of
      Diabetes and Digestive and Kidney Diseases and others.).
FAU - Adams, Ted D
AU  - Adams TD
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Davidson, Lance E
AU  - Davidson LE
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Litwin, Sheldon E
AU  - Litwin SE
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Kim, Jaewhan
AU  - Kim J
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Kolotkin, Ronette L
AU  - Kolotkin RL
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Nanjee, M Nazeem
AU  - Nanjee MN
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Gutierrez, Jonathan M
AU  - Gutierrez JM
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Frogley, Sara J
AU  - Frogley SJ
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Ibele, Anna R
AU  - Ibele AR
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Brinton, Eliot A
AU  - Brinton EA
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Hopkins, Paul N
AU  - Hopkins PN
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - McKinlay, Rodrick
AU  - McKinlay R
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Simper, Steven C
AU  - Simper SC
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
FAU - Hunt, Steven C
AU  - Hunt SC
AD  - From Intermountain Live Well Center Salt Lake, Intermountain Healthcare (T.D.A.),
      the Division of Cardiovascular Genetics, Department of Internal Medicine (T.D.A.,
      L.E.D., M.N.N., J.M.G., S.J.F., P.N.H., S.C.H.), Division of General Surgery,
      Department of Surgery (A.R.I.), and Division of Cardiovascular Medicine,
      Department of Internal Medicine (P.N.H.), University of Utah School of Medicine, 
      the Department of Health, Kinesiology and Recreation, College of Health,
      University of Utah (J.K.), the Utah Foundation for Biomedical Research and Utah
      Lipid Center (E.A.B.), and Rocky Mountain Associated Physicians (R.M., S.C.S.),
      Salt Lake City, and the Department of Exercise Sciences, Brigham Young
      University, Provo (L.E.D.) - all in Utah; the Medical University of South
      Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston
      (S.E.L.); Quality of Life Consulting, and the Department of Community and Family 
      Medicine, Duke University Health System, Durham, NC (R.L.K.); Western Norway
      University of Applied Sciences, Department of Health Studies, and Forde Hospital 
      Trust, Forde, and the Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg - 
      all in Norway (R.L.K.); and the Department of Genetic Medicine, Weill Cornell
      Medicine, Doha, Qatar (S.J.F., S.C.H.).
LA  - eng
GR  - M01 RR000064/RR/NCRR NIH HHS/United States
GR  - R01 DK055006/DK/NIDDK NIH HHS/United States
GR  - Z01 DK055006/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2018 Jan 04;378(1):95. PMID: 29303539
CIN - N Engl J Med. 2018 Jan 4;378(1):93. PMID: 29298158
CIN - N Engl J Med. 2018 Jan 04;378(1):93-4. PMID: 29303540
CIN - Am J Nurs. 2018 Jan;118(1):56. PMID: 29280807
CIN - Surg Obes Relat Dis. 2018 Feb;14 (2):247. PMID: 29254688
MH  - Adult
MH  - Aged
MH  - Body Weight
MH  - Diabetes Mellitus, Type 2/complications/epidemiology/prevention & control
MH  - Dyslipidemias/complications/prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - *Gastric Bypass
MH  - Humans
MH  - Hypertension/complications/prevention & control
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Obesity, Morbid/complications/mortality/*surgery
MH  - Remission Induction
MH  - Risk Factors
MH  - Suicide
MH  - *Weight Loss
MH  - Young Adult
PMC - PMC5737957
MID - NIHMS921565
EDAT- 2017/09/21 06:00
MHDA- 2017/09/28 06:00
CRDT- 2017/09/21 06:00
PHST- 2017/09/21 06:00 [entrez]
PHST- 2017/09/21 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
AID - 10.1056/NEJMoa1700459 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Sep 21;377(12):1143-1155. doi: 10.1056/NEJMoa1700459.

PMID- 28957843
OWN - NLM
STAT- MEDLINE
DCOM- 20180918
LR  - 20180918
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 102
IP  - 1
DP  - 2018 Jan
TI  - Chronic Liraglutide Administration Fails to Suppress Postprandial Glucagon Levels
      in Type 1 Diabetic Islet Allograft Recipients With Graft Dysfunction.
PG  - e39-e40
LID - 10.1097/TP.0000000000001964 [doi]
FAU - Vendrame, Francesco
AU  - Vendrame F
AD  - Diabetes Research Institute, University of Miami Miller School of Medicine,
      Miami, FL.
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine,
      University of Miami Miller School of Medicine, Miami, FL.
FAU - Padilla, Nathalia
AU  - Padilla N
AD  - Diabetes Research Institute, University of Miami Miller School of Medicine,
      Miami, FL.
FAU - Peixoto, Eduardo
AU  - Peixoto E
AD  - Diabetes Research Institute, University of Miami Miller School of Medicine,
      Miami, FL.
AD  - Department of Internal Medicine, Framingham Union Hospital, Metrowest Medical
      Center, Boston, MA.
FAU - Baidal, David
AU  - Baidal D
AD  - Diabetes Research Institute, University of Miami Miller School of Medicine,
      Miami, FL.
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine,
      University of Miami Miller School of Medicine, Miami, FL.
FAU - Lagari, Violet
AU  - Lagari V
AD  - Diabetes Research Institute, University of Miami Miller School of Medicine,
      Miami, FL.
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine,
      University of Miami Miller School of Medicine, Miami, FL.
FAU - Gil, Ana Alvarez
AU  - Gil AA
AD  - Diabetes Research Institute, University of Miami Miller School of Medicine,
      Miami, FL.
FAU - Mantero, Alejandro
AU  - Mantero A
AD  - Department of Public Health Sciences, University of Miami, Miami FL.
FAU - Messinger, Shari
AU  - Messinger S
AD  - Department of Public Health Sciences, University of Miami, Miami FL.
FAU - Ricordi, Camillo
AU  - Ricordi C
AD  - Diabetes Research Institute, University of Miami Miller School of Medicine,
      Miami, FL.
FAU - Alejandro, Rodolfo
AU  - Alejandro R
AD  - Diabetes Research Institute, University of Miami Miller School of Medicine,
      Miami, FL.
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine,
      University of Miami Miller School of Medicine, Miami, FL.
LA  - eng
GR  - KL2 TR000461/TR/NCATS NIH HHS/United States
GR  - U42 RR016603/RR/NCRR NIH HHS/United States
GR  - M01 RR016587/RR/NCRR NIH HHS/United States
GR  - R01 DK055347/DK/NIDDK NIH HHS/United States
GR  - UL1 TR000460/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Hypoglycemic Agents)
RN  - 839I73S42A (Liraglutide)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Diabetes Mellitus, Type 1/blood/*therapy
MH  - Glucagon/*blood
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - *Islets of Langerhans Transplantation
MH  - Liraglutide/*adverse effects
MH  - *Postprandial Period
PMC - PMC5741482
MID - NIHMS908110
EDAT- 2017/09/29 06:00
MHDA- 2018/09/19 06:00
CRDT- 2017/09/29 06:00
PMCR- 2019/01/01 00:00
PHST- 2019/01/01 00:00 [pmc-release]
PHST- 2017/09/29 06:00 [pubmed]
PHST- 2018/09/19 06:00 [medline]
PHST- 2017/09/29 06:00 [entrez]
AID - 10.1097/TP.0000000000001964 [doi]
PST - ppublish
SO  - Transplantation. 2018 Jan;102(1):e39-e40. doi: 10.1097/TP.0000000000001964.